Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10857657 | 0.81 | KDM4E (0.36) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL7520889 | 0.74 | CDK1 (0.31) | — | |
| SCHEMBL2968460 | 0.74 | KDM4E (0.35) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL432902 | 0.70 | INSR (0.43) | KDM4EALDH1A1GAAHPGD | |
| SCHEMBL10910402 | 0.70 | KDM4E (0.32) | KDM4E | |
| SCHEMBL99268 | 0.69 | KDM4E (0.35) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL5748053 | 0.69 | KDM4E (0.35) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL5170025 | 0.69 | KDM4E (0.35) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL1590661 | 0.69 | KDM4E (0.35) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL2009845 | 0.69 | KDM4E (0.35) | KDM4EALDH1A1GLAGAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 794 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3131914-B1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS LLC (US) | 2023-05-10 | — | — | EP | claimed |
| US-10202411-B2 | 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV | IDENIX PHARMACEUTICALS LLC (US) | 2019-02-12 | — | — | US | claimed |
| US-20180162898-A1 | 4'-OR NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS LLC (US) | 2018-06-14 | — | — | US | claimed |
| EP-3131914-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES FOR THE TREATMENT OF HCV | Idenix Pharmaceuticals LLC (US) | 2017-02-22 | — | — | EP | claimed |
| EP-1292603-B1 | METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS | IDENIX PHARMACEUTICALS LLC (US) | 2017-02-22 | — | — | EP | claimed |
| US-20170044205-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES NUCLEOTIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS, INC. | 2017-02-16 | — | — | US | claimed |
| EP-3083654-A1 | 4'-OR NUCLEOSIDES FOR THE TREATMENT OF HCV | Idenix Pharmaceuticals LLC (US) | 2016-10-26 | — | — | EP | claimed |
| US-20160280729-A1 | CYCLOPENTANE AND CYCLOPENTENE NUCLEOSIDE ANALOGS FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS LLC (US) | 2016-09-29 | — | — | US | claimed |
| WO-2015161137-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS, INC. (US) | 2015-10-22 | — | — | WO | claimed |
| WO-2015095419-A1 | 4'-OR NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS, INC. (US) | 2015-06-25 | — | — | WO | claimed |
| US-20050137161-A1 | Methods and compositions for treating hepatitis C virus | IDENIX PHARMACEUTICALS LLC | 2005-06-23 | — | — | US | claimed |
| US-6855821-B2 | Processes for preparing 1,3-dioxolane nucleosides | PHARMASSET, LTD. (US) | 2005-02-15 | — | — | US | claimed |
| US-20050031588-A1 | With purine or pyrimidine base; for use in combination with drugs that induce mutation in Flaviviridae at location other than mutation of nucleotide that results in change from serine to a different amino acid in highly conserved consensus sequence XRXSGXXXT of domain B of the RNA polymerase region | IDENIX PHARMACEUTICALS LLC | 2005-02-10 | — | — | US | claimed |
| US-20040254141-A1 | 2'-Fluoronucleosides | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-12-16 | — | — | US | claimed |
| US-20040181051-A1 | Process for the production of 3'-nucleoside prodrugs | STORER RICHARD (GB) | 2004-09-16 | — | — | US | claimed |
| WO-2004058792-A1 | PROCESS FOR THE PRODUCTION OF 3'-NUCLEOSIDE PRODRUGS | IDENIX (CAYMAN) LIMITED (KY) | 2004-07-15 | — | — | WO | claimed |
| WO-2004046331-A2 | 2’-BRANCHED NUCLEOSIDES AND FLAVIVIRIDAE MUTATION | IDENIX (CAYMAN) LIMITED (KY) | 2004-06-03 | — | — | WO | claimed |
| US-20040087806-A1 | Processes for preparing 1,3-dioxolane nucleosides | PHARMASSET, INC. | 2004-05-06 | — | — | US | claimed |
| WO-1992017485-A1 | PREPARATION OF 3'-SUBSTITUTED-2',3'-DIDEOXYNUCLEOSIDES AND 2'-DEOXYNUCLEOSIDES FROM ACYCLIC, ACHIRAL PRECURSORS | EMORY UNIVERSITY (US) | 1992-10-15 | — | — | WO | claimed |
| WO-1992010496-A1 | ENANTIOMERICALLY PURE β-L-(-)-1,3-OXATHIOLANE NUCLEOSIDES | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1992-06-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050031588-A1 | With purine or pyrimidine base; for use in combination with drugs that induce mutation in Flaviviridae at location other than mutation of nucleotide that results in change from serine to a different amino acid in highly conserved consensus sequence XRXSGXXXT of domain B of the RNA polymerase region | PNP, NSUN2, RNGTT | KDM4E 2422/4885ALDH1A1 3858/4885GLA 3159/4885 |
| US-20050137161-A1 | Methods and compositions for treating hepatitis C virus | HAVCR2, HCCS, PYGL | KDM4E 4340/4885ALDH1A1 929/4885GLA 474/4885 |
| US-20040254141-A1 | 2'-Fluoronucleosides | NSUN2, PNP, FDPS | KDM4E 2653/4885ALDH1A1 3361/4885GLA 3880/4885 |
| US-20160280729-A1 | CYCLOPENTANE AND CYCLOPENTENE NUCLEOSIDE ANALOGS FOR THE TREATMENT OF HCV | ZC3HAV1, HAVCR2, NSUN2 | KDM4E 2632/4885ALDH1A1 1679/4885GLA 3517/4885 |
| US-20040087806-A1 | Processes for preparing 1,3-dioxolane nucleosides | NUDT1, PNP, DPYD | KDM4E 3697/4885ALDH1A1 274/4885GLA 2216/4885 |
| US-20170044205-A1 | 3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES NUCLEOTIDES FOR THE TREATMENT OF HCV | RB1, NSUN2, METTL3 | KDM4E 754/4885ALDH1A1 1322/4885GLA 4184/4885 |
| US-20040181051-A1 | Process for the production of 3'-nucleoside prodrugs | PNP, GART, UMPS | KDM4E 2464/4885ALDH1A1 854/4885GLA 1226/4885 |
| US-10202411-B2 | 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV | RB1, NSUN2, METTL3 | KDM4E 786/4885ALDH1A1 1311/4885GLA 4185/4885 |
| US-20180162898-A1 | 4'-OR NUCLEOSIDES FOR THE TREATMENT OF HCV | NSUN2, NSUN3, ZC3HAV1 | KDM4E 692/4885ALDH1A1 483/4885GLA 2898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.